Juráček J, Staník M, Peltanová B, Adamcová S, Doležel J, Fedorko M, Radová L, Slabý O
Klin Onkol. 2018 Spring;31(Supplementum1):155-157.
Currently, there are no urinary-based tumour markers with sufficient sensitivity and specificity to replace cystoscopy in the detection of bladder cancer (BCA). Urinary microRNAs are emerging as clinically useful class of biomarkers for early and non-invasive detection of urologic malignancies.
In this study, 155 patients with BCA and 83 healthy controls were enrolled. Expression profiles of urinary miRNAs were obtained using Affymetrix miRNA microarrays and candidate miRNAs further validated in independent cohort using specific TaqMan assays and quantitative real-time polymerase chain reaction method.
Whole-genome profiling identified miRNA signature with significantly different concentrations in urine of BCA compared to controls (p < 0.01). In the independent validation phase of the study, three miRNAs were confirmed to have significantly higher levels in urine of patients with BCA in comparison with control groups (p < 0.0001). In addition, we observed significant decrease in two miRNAs (p < 0.01) concentrations in the urinary samples collected 3 months after surgery compared to pre-operative samples.
We identified and validated miRNAs to have significantly higher concentrations in urine of patients with BCA in comparison with controls. Our data have shown that urinary miRNAs could serve as sensitive and specific biomarkers enabling non-invasive detection of BCA.Key words: urinary microRNAs - biomarkers - bladder cancer The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study. The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers. This study was supported by Ministry of Health of the Czech Republic, grant No. 15-31071A. All rights reserved.Submitted: 19. 3. 2018Accepted: 20. 3. 2018.
目前,尚无基于尿液的肿瘤标志物具有足够的敏感性和特异性来替代膀胱镜检查用于膀胱癌(BCA)的检测。尿液微小RNA正成为用于泌尿系统恶性肿瘤早期和非侵入性检测的一类具有临床应用价值的生物标志物。
本研究纳入了155例BCA患者和83例健康对照。使用Affymetrix miRNA微阵列获得尿液miRNA的表达谱,并使用特异性TaqMan分析和定量实时聚合酶链反应方法在独立队列中进一步验证候选miRNA。
全基因组分析确定了BCA患者尿液中与对照组相比浓度有显著差异的miRNA特征(p < 0.01)。在研究的独立验证阶段,证实三种miRNA在BCA患者尿液中的水平显著高于对照组(p < 0.0001)。此外,我们观察到与术前样本相比,术后3个月采集的尿液样本中两种miRNA(p < 0.01)的浓度显著降低。
我们鉴定并验证了与对照组相比,BCA患者尿液中miRNA浓度显著更高。我们的数据表明,尿液miRNA可作为敏感且特异的生物标志物,实现BCA的非侵入性检测。关键词:尿液微小RNA - 生物标志物 - 膀胱癌 作者声明他们在研究中使用的药物、产品或服务方面不存在潜在利益冲突。编辑委员会声明该手稿符合ICMJE对生物医学论文的推荐。本研究得到了捷克共和国卫生部的支持,资助号为15 - 31071A。保留所有权利。提交日期:2018年3月19日 接受日期:2018年3月20日